Hepatic cirrhosis with thrombocytopenia
Conditions
Interventions
Treatment group:Conventional Western Medical Treatment Combined with Bloodletting Therapy at Ganshu (BL18) Acupoint
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 70 years old (inclusive), gender unrestricted. 2. Meet the Western medical diagnostic criteria for liver cirrhosis and thrombocytopenia related to liver diseases. 3. Platelet count: 20×109/L < platelet count < 50×109/L 4. The patient agrees to join this clinical study, voluntarily signed the informed consent form, and agrees to participate in all visits, examinations and treatments as required by the research protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with severe skin diseases; 2. History of liver malignancy or liver transplantation; received artificial liver treatment; 3. Received drugs such as rhTPO, granulocyte colony-stimulating factor, interleukin-11, or antiplatelet drugs to increase platelets within one month before enrollment; 4. Portal vein or deep vein thrombosis before treatment; 5. Patients with severe organic lesions in heart, brain, lung, kidney, etc.; 6. Hematological diseases, such as hematological malignancies, immune hemolytic anemia or idiopathic thrombocytopenic purpura; 7. Pregnant and lactating women, and women of childbearing age who refuse to maintain the contraceptive measures approved by the investigator throughout the study; 8. Patients with mental disorders or language expression and communication disorders; 9. Participated in other clinical trials within the past three months; 10. Lost to follow-up or incomplete data; 11. Other conditions deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients whose platelet count recovered to > 50×109/L after 2 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet count and changes from baseline on days 7 and 14 of treatment;Liver and kidney function on the 7th and 14th days and the changes relative to the baseline.;Blood routine tests on the 7th and 14th days and the changes relative to the baseline.;Coagulation function on the 7th and 14th days and the changes relative to the baseline;Thrombopoietin (TPO) and hepatocyte growth factor (HGF) on the 7th and 14th days;MELD on the 7th and 14th days and the changes relative to the baseline;Adverse events that occurred on the 7th and 14th days; | — |
Countries
China
Contacts
Public ContactLingying Huang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed